Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.

Ridolfi, Ruggero

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Mar 2002 - 1600-7 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0732-183X

10.1200/JCO.2002.20.6.1600 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Carmustine--administration & dosage
Cisplatin--administration & dosage
Dacarbazine--administration & dosage
Female
Humans
Interferon alpha-2
Interferon-alpha--administration & dosage
Interleukin-2--administration & dosage
Italy
Male
Melanoma--drug therapy
Middle Aged
Outpatients
Proportional Hazards Models
Prospective Studies
Quality of Life
Recombinant Proteins
Skin Neoplasms--drug therapy
Surveys and Questionnaires
Treatment Outcome